Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor

A composition for the treatment, prevention, or inhibition or pain, inflammation, or inflammation-associated disorder comprising a combination which includes an amount of a TNFα antagonist and an amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof which together constitute a pain or inflammation suppressing treatment or prevention effective amount of the combination.

A pharmaceutical composition comprising a pharmaceutically-acceptable excipient and a combination which includes, an amount of a TNFα antagonist and an amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof which together constitute a pain or inflammation suppressing treatment or prevention effective amount of the combination.

A kit that is suitable for use in the treatment, prevention or inhibition of pain, inflammation or inflammation-associated disorder, the kit comprises a first dosage form comprising a TNFα antagonist and a second dosage form comprising a cyclooxygenase-2 selective inhibitor or prodrug thereof, in quantities which comprise a therapeutically effective amount of the combination of the compounds for the treatment, prevention, or inhibition of pain, inflammation or inflammation-associated disorder.

A method for the treatment, prevention, or inhibition of a cardiovascular disease or disorder in a subject in need of such treatment, prevention, or inhibition, the method comprising administering to the subject a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNFα antagonist

A composition for the treatment, prevention, or inhibition of cardiovascular disease or disorder comprising a combination which includes an amount of a TNFα antagonist and an amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof which together constitute an amount of the combination that is effective for the treatment, prevention, or inhibition of a cardiovascular disease or disorder.

A pharmaceutical composition for the treatment, prevention, or inhibition of cardiovascular disease or disorder comprising a pharmaceutically-acceptable excipient and a combination which includes an amount of a TNFα antagonist and an amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof which together constitute an amount of the combination that is effective for the treatment, prevention, or inhibition of a cardiovascular disease or disorder.

A kit that is suitable for use in the treatment, prevention or inhibition of a cardiovascular disease or disorder, the kit comprising a first dosage form comprising a TNFα antagonist and a second dosage form comprising a cyclooxygenase-2 selective inhibitor or prodrug thereof, in quantities which comprise a therapeutically effective amount of the combination of the compounds for the treatment, prevention, or inhibition of a cardiovascular disease or disorder.

A method for the treatment, prevention, or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, the method comprising administering to the subject a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNFα antagonist which is selected from the group consisting of a compound that affects the synthesis of TNFα, a compound that inhibits the binding of TNFα with a receptor specific for TNFα, and a compound that interferes with intracellular signaling triggered by TNFα binding with a receptor.

A composition for the treatment, prevention, or inhibition of cancer comprising a combination which includes an amount of a TNFα antagonist and an amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof which together constitute an amount of the combination that is effective for the treatment, prevention, or inhibition of cancer.

A pharmaceutical composition for the treatment, prevention, or inhibition of cancer comprising a pharmaceutically-acceptable excipient and a combination which includes an amount of a TNFα antagonist and an amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof which together constitute an amount of the combination that is effective for the treatment, prevention, or inhibition of cancer.

A kit that is suitable for use in the treatment, prevention or inhibition of cancer, the kit comprising a first dosage form comprising a TNFα antagonist and a second dosage form comprising a cyclooxygenase-2 selective inhibitor or prodrug thereof, in quantities which comprise a therapeutically effective amount of the combination of the compounds for the treatment, prevention, or inhibition of cancer.

A therapeutic composition comprising an amount of a TNFα antagonist and an amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof which together constitute a therapeutic amount of the combination.